Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Infliximab
Remicade
Routinely available
NICE (TA187 (SMC 448/08))
01/05/2009
Indication
Treatment of severe, active Crohn' s disease in paediatric patients
Therapeutic Area
Gastro-intestinal system
Status Description
Routinely available in line with national guidance
Formulation
100mg powder for concentrate for solution for infusion
Comments
May 2009 - Previously approved as an ‘off-label medicine’ for this indication in May 2007. Added to the Additional List, for use in paediatrics. April 2019 (as per LJF) - Routinely available in line with national guidance. Included on the Additional List, for Specialist Use only.
Link to Advice
Advice Published
19/05/2010